GlassScriptPhysician profile
Robert S Siegel
NPI 1003985367
$4,810.94
in general payments reported to CMS, 2019-2025
48 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $36.85 · 2021: $259 · 2022: $856 · 2023: $730 · 2024: $1,123 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $447.09 | 2022-2025 | |
| Astellas Pharma US INC | $420.82 | 2019-2024 | Xtandi, Xospata |
| Merck Sharp & Dohme LLC | $376.96 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $309.59 | 2021-2022 | |
| Janssen Biotech, INC. | $254.84 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Incyte Corporation | $222.41 | 2022-2025 | Monjuvi, Pemazyre, Zynyz |
| Novartis Pharmaceuticals Corporation | $213.30 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $189.86 | 2019-2021 | |
| Genentech USA, INC. | $178.55 | 2022-2025 | Tecentriq, Venclexta, Tecentriq Hybreza |
| Daiichi Sankyo INC. | $174.86 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Celgene Corporation | $162.37 | 2019-2024 | Pomalyst |
| Abbvie INC. | $134.11 | 2024-2025 | |
| Gt Medical Technologies, INC | $125.20 | 2025 | Gammatile |
| Beone Medicines USA, INC. | $123.50 | 2025 | Brukinsa |
| Array Biopharma INC | $118.19 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $109.94 | 2023-2024 | Cabometyx |
| Medtronic, INC. | $101.41 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $98.59 | 2023-2025 | Opdivo |
| Sobi, INC | $85.18 | 2022-2025 | |
| Kite Pharma, INC. | $67.12 | 2023 | Yescarta |
| Emd Serono, INC. | $61.15 | 2020-2025 | |
| Coherus Oncology, INC. | $60.79 | 2024-2025 | Udenyca |
| Lilly USA, LLC | $52.66 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $52.06 | 2023-2024 | Xpovio |
| Beigene USA, INC. | $49.39 | 2020-2024 | Tevimbra |
| Foundation Medicine, INC. | $46.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $45.96 | 2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $43.76 | 2024 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $42.47 | 2024 | Onivyde, Somatuline Depot |
| Takeda Pharmaceuticals U.S.A., INC. | $39.22 | 2022-2025 | Fruzaqla |
| Genmab U.S., INC. | $37.72 | 2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $35.56 | 2025 | Qinlock, Romvimza |
| Pharmacyclics LLC, An Abbvie Company | $33.35 | 2022-2023 | Imbruvica |
| Amgen INC. | $30.90 | 2022-2023 | Lumakras |
| Aveo Pharmaceuticals, INC. | $25.47 | 2025 | |
| Legend Biotech USA INC. | $23.08 | 2025 | Carvykti |
| Gilead Sciences, INC. | $21.66 | 2024 | |
| Springworks Therapeutics, INC. | $21.21 | 2024 | Ogsiveo |
| Stemline Therapeutics INC. | $21.19 | 2024 | Orserdu |
| Syndax Pharmaceuticals, INC. | $20.84 | 2025 | |
| Taiho Oncology, INC. | $20.22 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.20 | 2025 | Monoferric |
| Cycle Pharmaceuticals INC | $19.20 | 2025 | Phyrago |
| Janssen Scientific Affairs, LLC | $18.33 | 2023 | Tecvayli, Darzalex |
| G1 Therapeutics, INC. | $15.93 | 2022 | |
| Rigel Pharmaceuticals, INC. | $14.17 | 2023 | Tavalisse, Rezlidhia |
| Servier Pharmaceuticals LLC | $13.71 | 2023 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.